Invitrogen, Stratagene Holding supply/service news

The U.S. District Court for the District of Texas issued a Markman ruling interpreting claims of IVGN's U.S. Patent No. 4,981,797 in a March patent infringement suit filed by IVGN. The patent, issued to IVGN's Life Technologies Inc. subsidiary, covers a process for producing transformable, competent cell lines by growing cells in growth medium at a temperature less than 37 degrees C. The court limited cell growth to temperatures between 18 and 32 degrees C, agreeing with Stratagene's interpretation of the patent claims. Strategene said its own method of producing cells includes growing the cells at 37 degrees C. ...